On the road to immunotherapy—prospects for treating head and neck cancers with checkpoint inhibitor antibodies

HIGHLIGHTS

• who: Frank J. Ward from the Institute of Medical Sciences, School of Medicine, Medical Sciences and Nutrition, University of Aberdeen, Foresterhill, University of Aberdeen, Foresterhill, Aberdeen, United Kingdom have published the Article: On the Road to Immunotherapy—Prospects for Treating Head and Neck Cancers With Checkpoint Inhibitor Antibodies, in the Journal: (JOURNAL)

SUMMARY

Perhaps the best known and most fundamental checkpoint receptor is CTLA-4 (CD152), which plays a role both in the priming of naïve T_cells and also control of effector T_cell response intensity. Analyses of immunogenic HNSCC, suggest that in . . .

 



If you want to have access to all the content you need to log in!

Thanks :)

Username or Email

Password

Remember me

Lost your password?

If you don't have an account, you can create one here.